Irinotecan-Induced Dysarthria

Irinotecan-Induced Dysarthria

Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the brain) following each administration of ir...

Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity

Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell line (HepG2) by comet assay. Materials and Methods: HepG2 were incubated with irinotecan (100 µM), heat-killed cells (0.025 µg/ml) + irinotecan...

protective role of lactobacillus plantarum a7 against irinotecan-induced genotoxicity

objective: irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. the present study evaluated the effect of lactobacillus plantarum a7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell line (hepg2) by comet assay. materials and methods: hepg2 were incubated with irinotecan (100 µm), heat-killed cells (0.025 µg/ml) + irinotecan...

Pure dysarthria, isolated facial paresis, or dysarthria-facial paresis syndrome.

BACKGROUND AND PURPOSE Pure dysarthria, isolated supranuclear facial paresis, and their combination without somatic motor dysfunction are rarely encountered clinical syndromes and have not yet been clearly characterized. METHODS Thirteen patients (9 men, 4 women; aged 33 to 72 [mean, 56] years) with unilateral strokes who developed dysarthria with or without facial paresis but without somatic...

Extending Dysarthria Research